Researchers have found that malignant and nonmalignant architectural distortion (AD) in breast imaging exams are better detected by (three-dimensional) 3D mammography than (two-dimensional) 2D, according to a study published online Sept. 21 in the American Journal of Roentgenology.

Diffusion-weighted imaging (DWI) could help differentiate between benign and malignant tumors and predict tumor recurrence in breast cancer patients, according to research published Oct. 4 in Academic Radiology. The authors noted that DWI may also serve as a beneficial supplement to contrast-enhanced breast MRI.

A 18F-FDG PET/CT scan can reveal previously undetected breast cancer in more than one-third of newly diagnosed male patients, according to research published Sept. 20 in the Journal of Nuclear Medicine.

Robert Horsley, MD, and colleagues found that almost half of women have never heard of the term “baseline mammogram," and two-thirds thought a baseline mammogram was insignificant in decreasing false positive rates and costs, according to research published Sept. 12 in the Journal of the American College of Radiology.

A Pennsylvania woman credits her early detection of breast cancer to a combination of ultrasound and mammography testing of her dense breast tissue, according to a report by the Scranton Times-Tribune in Pennsylvania.

Mammography screening for women with a history of breast cancer has declined since the U.S. Preventive Services Task Force (USPSTF) released its 2009 guidelines recommending that mammography examinations be deferred until a woman is at least 50 years old.  

In 2013, the American College of Radiology and Society of Breast Imaging created standardized curricula for U.S. breast imaging fellowships. Structural and organizational guidance for these fellowships, however, need improvement, according to an editorial published Aug. 14 in the Journal of the American College of Radiology.

While heart failure (HF) is an uncommon complication of breast cancer, a new study in the Journal of the American College of Cardiology notes individuals treated with trastuzumab-based chemotherapy have a higher risk for HF—but they are not monitored for it, despite recommendations.